ArticleProgress in biomaterials2023
Chitosan scaffolds with mesoporous hydroxyapatite and mesoporous bioactive glass.
Article in Progress in biomaterials, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 23 citations in OpenAlex.
- Recent Advances and Applications of Chitin and Chitosan Hydrogel Scaffolds in Tissue Engineering.Gels (Basel, Switzerland) · 2026Review
- Eggshell waste derived nano-hydroxyapatite/metakaolin composites for bone scaffold applications.RSC advances · 2026Article
- Molecular and physicochemical arrangement of chitosan-ibuprofen matrices for topical drug delivery on skin: preparation impact.RSC advances · 2026Article
- Mesoporous Bioactive Glasses: A Review on Structure-Directing-Based Synthesis, Characterization, and Biomedical Applications.Materials (Basel, Switzerland) · 2026Review
- Polycaprolactone/Doped Bioactive Glass Composite Scaffolds for Bone Regeneration.Journal of functional biomaterials · 2025Article
- Balanced enhancement of antibacterial activity and biocompatibility in chitosan-vancomycin 3D-printed scaffolds through mesoporous bioactive glass addition.Journal of drug delivery science and technology · 2025Article
- Polysaccharide Hydroxyapatite (Nano)composites and Their Biomedical Applications: An Overview of Recent Years.ACS omega · 2024Review
- Current and Future Perspectives of Bioactive Glasses as Injectable Material.Nanomaterials (Basel, Switzerland) · 2024Review
- Recent Advancements in Bone Tissue Engineering: Integrating Smart Scaffold Technologies and Bio-Responsive Systems for Enhanced Regeneration.International journal of molecular sciences · 2024Review
- Advances in Biomimetic Scaffolds for Hard Tissue Surgery.Biomimetics (Basel, Switzerland) · 2024Article
- Chitosan Microspheres Loaded with Curcumin and Gallic Acid: Modified Synthesis, Sustainable Slow Release, and Enhanced Biological Property.Current microbiology · 2023Article
- Mesoporous Whitlockite: Synthesis, characterization, and in vitro biocompatibility for bone tissue engineering applications.Journal of oral biology and craniofacial researchArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
Bone regeneration is one of the most well-known fields in tissue regeneration. The major focus concerns polymeric/ceramic composite scaffolds. In this work, several composite scaffolds based on chitosan (CH), with low and high molecular weights, and different concentrations of ceramics like mesoporous bioactive glass (MBG), mesoporous hydroxyapatite (MHAp) and both MBG and MHAp (MC) were produced by lyophilization. The purpose is to identify the best combination regarding optimal morphology and properties. The tests of the scaffolds present a highly porous structure with interconnected pores. The compression modulus increases with ceramic concentration in the scaffolds. Furthermore, the 75%MBG (835 ± 160 kPa) and 50%MC (1070 ± 205 kPa) samples are the ones that mostly enhance increases in mechanical properties. The swelling capacity increases with MBG and MC, respectively, to 700% and 900% and decreases to 400% when MHAp concentration increases. All scaffolds are non-cytotoxic at 12.5 mg/mL. The CHL scaffolds improve cell adhesion and proliferation compared to CHH, and the MC scaffold samples, show better results than those produced with just MBG or MHAp. The composite scaffolds of chitosan with MBG and MHAp, have revealed to be the best combination due to their enhanced performance in bone tissue engineering.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.